In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.
In season 5, episode 3 of Targeted Talks, Ben Derman, MD, assistant professor of medicine at the University of Chicago Medical Center, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease (MRD) monitoring.
Specifically, the discussion delves deep into the game-changing trial (NCT02969837) investigating MRD in the peripheral blood of patients with multiple myeloma. An analysis of the study recently evaluated the concordance and prognostic significance of early MRD status after 4 cycles of treatment with elotuzumab (Empliciti), carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (Elo-KRd) by next-generation sequencing in the bone marrow and peripheral blood and by International Myeloma Working Group response criteria. Findings were presented at the 2023 American Society of Hematology Annual Meeting.
"Peripheral blood testing, while not as sensitive as bone marrow, could offer a less invasive alternative for patients, potentially guiding treatment decisions more effectively," Derman explains.
The trial employed an MRD-adapted design to determine the duration of carfilzomib treatment based on MRD status, demonstrating a personalized treatment approach guided by MRD assessment.
Pivotal findings from this trial showed the association of peripheral blood MRD status with progression-free survival (PFS). Patients with peripheral blood MRD positivity exhibited inferior PFS outcomes compared with those with peripheral MRD negativity. The strong correlation between bone marrow and peripheral blood MRD status indicates the potential utility of peripheral blood MRD testing as a reliable indicator of disease burden and treatment response.
These findings underscore the transformative potential of peripheral blood MRD testing in the management of multiple myeloma, paving the way for personalized treatment strategies and improved patient outcomes.
Gain more insights into the exciting advancements in MRD detection, including next-generation sequencing and mass spectrometry, offering patients a less invasive alternative for monitoring disease progression in this episode.
Fellow's Perspective: Patient Case of Newly Diagnosed Multiple Myeloma
November 13th 2024In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about their choices for a patient with transplant-eligible multiple myeloma and the data behind their decisions.
Read More
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
Roundtable Roundup: Early-Line Use of CAR T-cell Therapy in Multiple Myeloma
October 22nd 2024In separate, live virtual events, Doris Hansen, MD, and Leyla O. Shune, MD, discuss options for a patient with relapsed/refractory multiple myeloma and how often participants use chimeric antigen receptor (CAR) T-cell therapy.
Read More